If youd like to support Ricky and his family, your contribution ~big or small~ helps provide practical assistance and continued support
Data for this patient's case was obtained through an electronic chart review
This very short action limited the initial enthusiasm for the possible usefulness of incretins for the treatment of T2DM, and in turn stimulated the development of both GLP1 agonists resistant to DPP-4, with a longer half-life and of DPP-4 inhibitors that prolong the half-life of native incretins
In conclusion, GLP-1RA is a promising candidate drug therapy for pediatric MASLD, and patients may benefit from metabolic improvement even if the liver disease ameliorating effects are not yet clear
Wang W, Lin W, Hong B, Li X, Zhang M, Zhang L, et al